WallStSmart

Merck & Company Inc (MRK)vsUtah Medical Products Inc (UTMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 173115% more annual revenue ($65.01B vs $37.53M). UTMD leads profitability with a 28.9% profit margin vs 28.1%. MRK appears more attractively valued with a PEG of 3.36. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

UTMD

Hold

46

out of 100

Grade: D+

Growth: 2.0Profit: 8.0Value: 3.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued
UTMDSignificantly Overvalued (-22.8%)

Margin of Safety

-22.8%

Fair Value

$51.90

Current Price

$65.42

$13.52 premium

UndervaluedFair: $51.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

UTMD3 strengths · Avg: 8.3/10
Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Operating MarginProfitability
29.4%8/10

Strong operational efficiency at 29.4%

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

UTMD4 concerns · Avg: 2.3/10
Market CapQuality
$207.06M3/10

Smaller company, higher risk/reward

PEG RatioValuation
4.252/10

Expensive relative to growth rate

Revenue GrowthGrowth
-10.2%2/10

Revenue declined 10.2%

EPS GrowthGrowth
-11.0%2/10

Earnings declined 11.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : UTMD

The strongest argument for UTMD centers on Profit Margin, Price/Book, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 29.4%.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : UTMD

The primary concerns for UTMD are Market Cap, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

MRK profiles as a value stock while UTMD is a declining play — different risk/reward profiles.

UTMD carries more volatility with a beta of 0.35 — expect wider price swings.

MRK is growing revenue faster at 5.0% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 46/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Utah Medical Products Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.

Want to dig deeper into these stocks?